Analysis of HER-2/neu amplification in endometrial carcinoma by chromogenic in situ hybridization. Correlation with fluorescence in situ hybridization, HER-2/neu, p53 and Ki-67 protein expression, and outcome

Modern Pathology

Volumn 17, Issue 3, 2004, Pages 277-287

  Peiro G ^a,b   Mayr, D ^a   Hillemanns, P ^a   Lohrs U ^a   Diebold, J ^a  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^b HOSPITAL GENERAL UNIVERSITARIO DE ALICANTE   (Spain)

Author keywords

CISH; Endometrial carcinoma; FISH; HER 2 neu; Ki 67; p53

Indexed keywords

DIGOXIGENIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; KI 67 ANTIGEN; PROTEIN P53;

ADULT; AGED; ARTICLE; CANCER GRADING; CANCER STAGING; CANCER SURVIVAL; CELL SURVIVAL; CONTROLLED STUDY; ENDOMETRIUM CARCINOMA; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE AMPLIFICATION; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; MAJOR CLINICAL STUDY; MICROSCOPY; ONCOGENE NEU; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; COMPARATIVE STUDY; ENDOMETRIUM TUMOR; GENETICS; METABOLISM; METHODOLOGY; MIDDLE AGED; PROTO ONCOGENE; SURVIVAL;

ADULT; AGED; AGED, 80 AND OVER; ENDOMETRIAL NEOPLASMS; FEMALE; GENE AMPLIFICATION; GENES, ERBB-2; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; IN SITU HYBRIDIZATION, FLUORESCENCE; KI-67 ANTIGEN; MIDDLE AGED; RECEPTOR, ERBB-2; SURVIVAL ANALYSIS; TUMOR SUPPRESSOR PROTEIN P53;

EID: 7444228551     PISSN: 08933952     EISSN: 15300285     Source Type: Journal    
DOI: 10.1038/modpathol.3800006     Document Type: Article

References (34)

1. Schechter AL, Hung MC, Vaidyanathan L, et al. The neu gene: an erbB-homologous gene distinct from and unlinked to the gene encoding the EGF receptor. Science 1985;229:976-978.
2. Slamon DJ, Godolphin W, Jones LA, et al. Studies of the HER-2/neu Proto-oncogene in human breast and ovarian cancer. Science 1989;244:707-712.
3. Kakar S, Puangsuvan N, Stevens JM, et al. HER-2/neu assessment in breast cancer by immunohistochemistry and fluorescence in situ hybridization: comparison of results and correlation with survival. Mol Diagn 2000;5:199-207.
4. Heinze T, Jonas S, Karsten A, et al. Determination of the oncogenes p53 and c-erb B2 in the tumour cytosols of advanced hepatocellular carcinoma (HCC) and correlation to survival time. Anticancer Res 1999;19:2501-2503.
5. Kristiansen G, Yu Y, Petersen S, et al. Overexpression of c-erb B2 protein correlates with disease-stage and chromosomal gain at the c-erb B2 locus in non-small cell lung cancer. Eur J Cancer 2001;37:1089-1095.
6. Ross JS, Sheehan C, Heiner-Bucham AM, et al. Prognostic significance of HER-2/neu gene amplification status by fluorescence in situ hybridization of prostate carcinoma. Cancer 1997;79:2162-2170.
7. Press MF, Bernstein L, Thomas PA, et al. HER-2/neu gene amplification characterized by fluorescent in situ hybridization: poor prognosis in node negative breast carcinomas. J Clin Oncol 1997;15:2894-2904.
8. Slamon D, Leyland-Jones B, Shak S, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001;344:783-792.
9. Ross JS, Fletcher JA. HER-2/neu (c-erb B2) gene and protein in breast cancer. Am J Clin Pathol 1999;112: S53-S67.
10. Czerwenka K, Lu Y, Heuss F. Amplification and expression of the HER-2/neu oncogene in normal, hyperplastic, and malignant endometria. Int J Gynecol Pathol 1995;14:98-106.
11. Jacobs TW, Gown AM, Yazijy H, et al. Comparison of fluorescence in situ hybridization and immunohistochemistry for the evaluation of HER2/neu in breast cancer. J Clin Oncol 1999;17:1974-1978.
12. Lebeau A, Deimling D, Kaltz C, et al. HER-2/neu analysis in archival tissue samples of human breast cancer: comparison of immunohistochemistry and fluorescence in situ hybridization. J Clin Oncol 2001;19:354-363.
13. Hanna WM, Kahn HJ, Pienkowska M, et al. Defining a test for HER-2/neu evaluation in breast cancer in the diagnostic setting. Mod Pathol 2001;14:677-685.
14. Mass R, Sanders C, Charlene K, et al. The concordance between the clinical trials assay (CTA) and fluorescence in situ hybridization (FISH) in the Herceptin Pivotal Trials [abstract]. Proc ASCO 2000;19:75A.
15. Tubbs RR, Pettay J, Roche P, et al. Concomitant oncoprotein detection with fluorescence in situ hybridization (CODFISH): a fluorescence-based assay enabling simultaneously visualization of gene amplification and encoded protein expression. J Mol Diagn 2000;2:78-83.
16. Tanner M, Gancberg D, Di Leo A, et al. Chromogenic in situ hybridization: a practical alternative fur fluorescence in situ hybridization to detect HER-2/neu oncogene amplification in archival breast cancer samples. Am J Pathol 2000;157:1467-1472.
17. Ioffe OB, Papadimitriou JC, Drachenberg CB. Correlation of proliferation indices, apoptosis, and related oncogene expression (bcl-2 and c-erb B2) and p53 in proliferative, hyperplasic, and malignant endometrium. Hum Pathol 1998;29:1150-1159.
18. Reinartz JJ, George E, Lindgren BR, et al. Expression of p53, transforming growth factor receptor, and c-erb B2 in endometrial carcinoma and correlation with survival and known predictors of survival. Hum Pathol 1994;25:1075-1083.
19. Pisani AL, Barbuto DA, Chen D, et al. HER-2/neu, p53, and DNA analyses and prognosticators for survival in endometrial carcinoma. Obstet Gycecol 1995;85:729-734.
20. Saffari B, Jones LA, el-Naggar A, et al. Amplification and overexpression of HER-2/neu (c-erb B2) in endometrial cancers: correlation with overall survival. Cancer Res 1995;55:5693-5698.
21. Riben MW, Malfetano JH, Nazeer T, et al. Identification of HER-2/neu oncogene amplification by fluorescence in situ hybridization in stage I endometrial carcinoma. Mod Pathol 1997;10:823-831.
22. Backe J, Gassel AM, Krebs S, et al. Immunohistochemically detected HER-2/neu expression and prognosis in endometrial carcinoma. Arch Gynecol Obstet 1997;259:189-195.
23. Rolitsky CD, Theil KS, McGaughy VR, et al. HER-2/neu amplification and overexpression in endometrial carcinoma. Int J Gynaecol Pathol 1999;18:138-143.
24. Heffner HM, Freedman AN, Asirwatham JE, et al. Prognostic significance of p53, PCNA, and HER-2/neu in endometrial carcinoma. Eur J Gynaecol Oncol 1999;20:8-12.
25. Coronado PJ, Vidart JA, Lopez-Asenjo JA, et al. p53 overexpression predicts endometrial carcinoma recurrence better than HER-2/neu overexpression. Eur J Obstet Gynecol Reprod Biol 2001;98:103-108.
26. Wolf HK, Stober C, Hohenfellner R, et al. Prognostic value of p53, p21/WAF1, Bcl-2, Bax, Bak, and Ki-67 immunoreactivityin pT1 G3 urothelial bladder carcinomas. Tumour Biol 2001;22:328-336.
27. Ito K, Sasano H, Matsunaga G, et al. Correlation between p21 expression and clinicopathological findings, p53 gene and protein alterations, and survival in patients with endometrial carcinomas. J Pathol 1997;183:318-324.
28. Salvesen HB, Iversen OE, Akslem LA. Prognostic significance of angiogenesis and Ki-67, p53, and p21 expression: a population-based endometrial carcinoma study. J Clin Oncol 1999;17:1382-1390.
29. Kallakury BVS, Ambros RA, Hayner-Buchan AM, et al. Cell proliferation-associated proteins in endometrial carcinomas, including papillary serous and endometrioid subtypes. Int J Gynecol Pathol 1998;17:320-326.
30. Geisler JP, Geisler HE, Miller GA, et al. MIB-1 in endometrial carcinoma: prognostic significance with 5-year follow-up. Gynecol Oncol 1999;75:432-436.
31. Kurman RJ, Zaino RJ, Norris HJ. Endometrial carcinoma. In: Blaustein's Pathology of the Female Genital Tract. Kurman RJ (ed). Springer-Verlag: New York, 1994; p 441.
32. FIGO stages: 1988 Revision. Gynecol Oncol 1989;35:125-127.
33. Wang S, Hossein Saboorian M, Frenkel EP, et al. Aneusomy 17 in breast cancer its role in HER-2/neu protein expression and implication for clinical assessment of HER-2/neu status. Mod Pathol 2002;15:137-145.
34. McCormick SR, Lillemoe TJ, Beneke J, et al. HER-2 assessment by immunohistochemical analysis and fluorescence in situ hybridization: comparison of HercepTest and PathVysion commercial assays. Am J Clin Pathol 2002;117:935-943.